Current Studies

Here is a list of some of our current studies. For additional studies, please visit RecruitMe.

 

  • Principal Investigator

    Brian A. Fallon, MD
    Why do some patients recover quickly after Lyme disease while others develop chronic symptoms? To answer this question, we need to enroll patients at different stages of illness -- early at the initial infection when it affects the skin, joints, nervous system or heart, and later as well to see who has recovered and who has persistent symptoms. Some have only a mild illness associated with the rash. Others are quite ill and may not be sure when they were infected. We follow each patient carefully over 2 years.
  • Principal Investigator

    Helen Blair Simpson, MD, PhD
    For this study, eligible participants will be asked questions about their symptoms and complete a medical evaluation. You will receive a medication, and be monitored by medical professionals. You will also be asked to complete questionnaires. The purpose of this study is to assess to evaluate a medication for the treatment of OCD.
  • Principal Investigator

    J. John Mann, MD
    Depression affects 15 million Americans each year. Depression and suicidal behavior are transmitted in families due to a combination of genes and environment. Depressive illness and the risk of suicidal behavior are associated with altered brain function that we can detect with brain imaging. Therefore, this study aims to examine brain function in adults who have a relative who has suffered from depression and made a suicide attempt. The goal of the study is to detect which adult children are at risk of developing depression and who is not going to develop depression.
  • Principal Investigator

    J. John Mann, MD
    Depression affects 15 million Americans each year. Depression and suicidal behavior are transmitted in families due to a combination of genes and environment. Depressive illness and the risk of suicidal behavior are associated with altered brain function that we can detect with brain imaging. Therefore, this study aims to examine brain function in adults who have a relative who has suffered from depression and made a suicide attempt. The goal of the study is to detect which adult children are at risk of developing depression and who is not going to develop depression.
  • Principal Investigator

    Jonathan E. Posner, MD
    In this study, we are trying to learn more about how stimulant medication produces an improvement in emotional lability (frequent mood changes and excessive emotional reactions) in patients with Attention Deficit Hyperactivity Disorder (ADHD.) Although ADHD is primarily associated with inattention, hyperactivity, and impulsivity, emotional ability plays a crucial role in the disorder.
  • The Neurocognition of Language Laboratory is seeking children from 6 12 years of age to participate in a brain study of visual-sensory processing. We will use a technique called electroencephalography (EEG) to measure the brains electrical activity by placing small electrodes that rest on the scalp. EEG is pain-free, safe, and non- invasive. We are looking for children with autism spectrum disorder (ASD) who do not take psychiatric medications and neurotypical children without psychiatric diagnoses.

  • Principal Investigator

    Frances R. Levin, MD
    This study will test a computer-based behavioral intervention to decrease cocaine use. Those who fail to achieve cocaine abstinence after the first 4 weeks while receiving the behavioral treatment will continue the behavioral treatment and be randomly assigned to one of two groups (one group will receive Adderall-XR (MAS-ER) and the other group will receive placebo (an inactive sugar pill)), over the course of 10 weeks. Patients will be asked to come into the clinic for outpatient treatment 3 times per week.
  • Principal Investigator

    Martin J. Lan, MD, PhD
    We are trying to understand what causes bipolar disorder and how medications treat bipolar depression. If you participate, you will have two different brain scans (MRI and PET scan). You will also have antidepressant treatment for free. We will then be able to see whether information on the brain scans connects with how people do on the medications. The medications are common, and are not experimental. You will be able to discuss the treatment with Dr. Lan before starting the study to make sure that it is the proper treatment for you.
  • Principal Investigator

    Martin J. Lan, MD, PhD
    We are trying to understand what causes bipolar disorder and how medications treat bipolar depression. Particularly, we are looking at the importance of inflammation in the process. If you participate, you will have genetic testing and three different brain scans (one MRI and two PET scans). You will also receive an experimental medication for your depression named N-acetyl cysteine (NAC). Please contact us if you are interested in participating.
  • Principal Investigator

    Yuval Neria, PhD
    Columbia University Medical Center is presently recruiting individuals who have experienced trauma to participate in an fMRI research study. For your participation, you will receive up to $270 and an opportunity to advance research in the area of trauma and PTSD. This study involves two visits.
  • Principal Investigator

    Yuval Neria, PhD
    Columbia University Medical Center is presently recruiting healthy individuals to participate in an fMRI research study. For your participation, you will receive up to $270 and an opportunity to advance research in the area of trauma and PTSD. This study involves two visits.
  • Principal Investigator

    Guillermo Horga, MD, PhD
    This study intends to learn more about the symptoms of psychosis and beliefs. The study involves clinical interviews, clinical chart review, computer tests, and magnetic resonance imaging (MRI) scans.
  • Principal Investigator

    Franklin R. Schneier, MD
    We are currently enrolling individuals with social anxiety disorder to participate in this study. The purpose of this study is to assess whether a brief computer-based research treatment helps improve social anxiety symptoms. For eligible participants, this study will involve a brief, novel research treatment for social anxiety, delivered in 8 or 12 sessions over the course of 4 or 8 weeks.Participants will receive payment for completing study assessments. The study will also assess the effect of research treatments on brain activity using a scan called magnetic resonance imaging (MRI).
  • Principal Investigator

    Rachel Marsh, PhD
    This research study aims to identify a distinct pattern of brain abnormalities that underlie OCD by assessing the changes in brain circuits following treatment with cognitive-behavioral therapy (CBT) in children and adolescents. Study Procedures: A free, thorough diagnostic evaluation ~ A full course of CBT (12-16 sessions) at no cost ~ fMRI scans before and after CBT treatment ~ Three months of free follow-up treatment for OCD including medical care. Study evaluations and treatment will be provided at no cost to you.
  • Principal Investigator

    Michael G. Wheaton, PhD
    The purpose of this study is to learn more about how individuals with anxiety respond to a stress reactivity task. This study may help us to better understand the brain basis of anxiety so that we can improve anxiety treatments. You will be asked to complete a stress reactivity task and questionnaires about your symptoms and health for compensation of up to $100.
  • Principal Investigator

    Patrick J. Brown, PhD
    The goal of this open-administration treatment study of escitalopram (or duloxetine) is to evaluate the effect of antidepressant medication on treating the syndrome of frailty in older adults with depressive symptoms. Patients with significant depressive symptoms and 1 or more symptoms of the frailty syndrome (exhaustion, decreased energy, weight loss, decreased grip strength, and slow/unsteady gait) will be evaluated and treated with approved antidepressant medication for 8 weeks to test whether antidepressant medication improves both the syndrome of frailty and depressive symptoms.
  • Principal Investigator

    Brian A. Fallon, MD
    This long-term goal in this study is to reduce the number of patients who develop symptoms of chronic Lyme disease (also known as Post-treatment Lyme Syndrome) by identifying better tests and by understanding the immunologic, rheumatologic, and neurologic impact of this illness over time. This can only be done by comparing those patients who recover fully to those who experience ongoing symptoms, as well as to healthy controls. While at the Center, we will collect blood and conduct very careful clinical assessments.
  • Principal Investigator

    Joanna E. Steinglass, MD
    This NIMH-funded research study examines whether there are differences in the brain when people with eating disorders make decisions about food. We hope to understand the neurobiology of eating disorders so that we can improve treatment. Participation includes computer tasks, brain imaging (MRI), and a measure of eating behavior. Eligible individuals will receive inpatient or outpatient treatment at no cost.
  • Principal Investigator

    David J. Hellerstein, MD
    This is a pre-marketing (Phase 2A) multi-site study of an investigational drug, ganaxolone, as a potential treatment for non-psychotic post-partum depression. Eligible subjects who agree by signing informed consent will spend four days on the 5-South Research Unit (5-S) of the New York State Psychiatric Institute. For 60 hours they will have an tube in a vein into which randomly assigned intravenous ganaxolone or placebo will be infused. Mood and adverse events will be assessed throughout their 5-S stay and at weeks 1, 2, 3 and 4. The initial cohort of 10 patients have completed.
  • Principal Investigator

    Sandra Comer, PhD
    Healthy heroin users (men and women, ages 21-59) are needed for an eight-week inpatient study investigating medication effects at the NY State Psychiatric Institute. Earn approximately $6,550 - $7,350.
  • Principal Investigator

    Joanna E. Steinglass, MD
    A research study at the New York State Psychiatric Institute and Columbia University Medical Center is looking for healthy teens between the ages of 14 and 18 years to participate in a study about food. Come in to the lab three times over the course of two years and get up to $250 each time for your participation. For more information and to see if you are eligible, call the Columbia Center for Eating Disorders at 646 774 8066.
  • Principal Investigator

    J. John Mann, MD
    This research study uses brain imaging to explore the biological causes of depression and suicidal behavior. The investigators hope to develop a better understanding of how people who attempt suicide differ from those who don't in order to improve prevention. Participation includes brain imaging scans (MRI and PET), neuropsychological tasks and clinical assessment. Eligible individuals will be compensated up to $475.
  • Principal Investigator

    J. John Mann, MD
    This research study uses brain imaging to explore the biological causes of major depression and why some people feel suicidal or may act on such thoughts. The investigators hope to develop a better understanding of how people who feel depressed and suicidal cope with their feelings to improve treatment and prevention. Individuals may qualify if they have depression with or without suicidal thoughts or any history of suicide attempts. Participation involves a detailed diagnostic set of interviews, brain imaging scans (MRI and PET) and neuropsychological tasks.
  • Principal Investigator

    Bret R. Rutherford, MD
    In this research study, you may receive treatment for depression with an FDA approved medication called escitalopram (Lexapro) or placebo. Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI) medication that appears to help with symptoms of depression by increasing the availability of specific chemicals in the brain. A placebo is a sugar pill. The purpose of this study is to determine how treatment response may change depending on how studies are designed.
  • Principal Investigator

    David J. Hellerstein, MD
    This study is a double-blind and placebo-controlled study to assess its efficacy of the new drug Lumateperone for patients with Major Depressive Episodes associated with Bipolar I and Bipolar II disorder. Lumateperone is thought to exert its antidepressant effect through interaction with sereotogenic, dopaminergic, and glutamergic neurotransmitter targets.This is a 6 week outpatient study where patients will be given Lumateperone pills to take daily. A single dose will be taken each evening, starting with the evening of their baseline period.
  • Principal Investigator

    Frances R. Levin, MD
    The study is an outpatient treatment study of the safety and benefit of extended-release mixed amphetamine salt (Adderall-XR) in the treatment of individuals with cannabis use disorder and Attention Deficit/Hyperactivity Disorder (ADHD). The study is a 13-week trial and requires participants to come twice per week. The primary objective of the study is to determine the safety and effectiveness of Adderall-XR in decreasing marijuana use and in promoting a decrease in ADHD symptoms.
  • Principal Investigator

    Frances R. Levin, MD
    This study proposes to recruit patients with Opioid Use Disorder (OUD) seeking treatment into our program of a 5 day outpatient detoxification and naltrexone induction followed by a relapse-prevention treatment with Extended release-naltrexone (XR-NTX) for 8 weeks.
  • Principal Investigator

    Brian A. Fallon, MD
    The CDC estimates that 10-20% of patients with Lyme disease will go on to have chronic symptoms despite having had appropriate treatment, a condition known as Post-Treatment Lyme Disease Syndrome (PTLDS). While there is currently no known cure, various therapies are being investigated.
  • Principal Investigator

    Joshua T. Kantrowitz, MD
    We will evaluate the D-cycloserine (DCS) and lurasidone with MRI measurement of brain responses to DCS. DCS is a drug that works on the same brain receptor as ketamine. DCS is not approved by the FDA for bipolar depression. Study participants will receive a dose of lurasidone or placebo in one MRI and a dose of DCS in another, followed by an optional follow-up four week phase of lurasidone plus DCS. We hope to develop a better understanding of how these medications work.
  • Principal Investigator

    Rachel Marsh, PhD
    Research Study using MRI to examine learning and memory in persons who have not been diagnosed with any neurological or psychiatric disorders. All ethnic groups can participate. Must have no history of psychological or neurological disorders. WHERE? The study will take place at the New York State Psychiatric Institute, 1051 Riverside Drive in Manhattan. WHAT WILL HAPPEN? Participation in our study involves three parts: interviews, games and puzzles, and an MRI scan. The total compensation for your time is between $261-522.
  • Principal Investigator

    Jeffrey M. Miller, MD
    The goal of this study is to examine how effective and well-tolerated a possible new treatment for individuals who injure themselves frequently will be. We are studying a minimal-risk form of electrical brain stimulation called transcranial direct current stimulation, or tDCS. Previous studies using tDCS have shown that it is helpful in treating conditions like depression and chronic pain. tDCS is administered using two small electrodes that are applied to the scalp. A low current is applied to the electrodes using a battery-operated device.
  • Principal Investigator

    Jeffrey M. Miller, MD
    The goal of this study is to examine how effective and well-tolerated a possible new treatment for individuals who injure themselves frequently will be. We are studying a minimal-risk form of electrical brain stimulation called transcranial direct current stimulation, or tDCS. Previous studies using tDCS have shown that it is helpful in treating conditions like depression and chronic pain. tDCS is administered using two small electrodes that are applied to the scalp. A low current is applied to the electrodes using a battery-operated device.
  • Principal Investigator

    Jeffrey M. Miller, MD
    The goal of this study is to examine how effective and well-tolerated a possible new treatment for individuals who injure themselves frequently will be. We are studying a minimal-risk form of electrical brain stimulation called transcranial direct current stimulation, or tDCS. Previous studies using tDCS have shown that it is helpful in treating conditions like depression and chronic pain. tDCS is administered using two small electrodes that are applied to the scalp. A low current is applied to the electrodes using a battery-operated device.
  • Principal Investigator

    Barbara H. Stanley, PhD
    This study conducts behavioral tasks to explore the biological causes of depression and suicidal behavior. We hope to develop a better understanding of how people who feel depressed and suicidal cope with their feelings so we can improve treatment and prevention. Participants can have depression with or without a suicidal thoughts or any history of suicide attempts. Participation involves clinical assessments, a week-long phone survey, a stress test and computer games.
  • Principal Investigator

    Randy P. Auerbach, PhD
    This study uses smartphone technology to better understand changes in adolescent moods over time. As a participant in our study, we would: (a) interview your child about current and past thoughts, feelings, and behaviors and (b) collect data from your child's smartphone for 6 months through an app called the Effortless Assessment of Risk States (EARS; which would be installed during the initial study visit after you learned more about the study and provided permission).
  • Principal Investigator

    Jeremy Veenstra-Vanderweele, MD
    The Translational Medicine Program at the Center for Autism and the Developing Brain is recruiting individuals with autism from 5 17 years of age with an IQ over 70 to participate in our study called aV1ation. The purpose of this study is to test an investigational medicine that blocks a hormone receptor in the brain linked to the control of socialization, stress, anxiety and aggression. We want to see if this medicine is effective as a treatment to help improve social functioning in children with ASD.
  • Principal Investigator

    Jonathan Stewart, MD
    Previous data suggest some depressed patients act as if their internal biological clock is out of sync with the outside world and re-aligning their clock with the timing of sunlight lessens their depressed mood and accompanying depressive symptoms. This protocol may lead to remission during the first week of treatment while causing minimal problems. Which treatment condition a participant will receive will be determined randomly (i.e., by chance, essentially a computerized flip of a coin).
  • Principal Investigator

    Helen Blair Simpson, MD, PhD
    The Center for OCD and Related Disorders and the Institute of Genomic Medicine is conducting a study to look for genetic causes of OCD. Our goal is to look at the genes of individuals with OCD to see if we can identify what may have put those individuals at risk for OCD. Participants will receive a clinical evaluation at no cost, a blood draw (up to 2 tablespoons) and compensation for their time. Significant findings from these genetic tests will be reported back to participants (if they chose to be notified of results).
  • Principal Investigator

    Bret R. Rutherford, MD
    In this research study, you will be fitted with hearing aids that may be fully tuned to improve your hearing (full dose) or may be only partially tuned and not likely to substantially improve your hearing (low dose). You will receive a free hearing aid that will be at full dose at the end of the 12 week study. You will also receive treatment for depression with an FDA approved medication called escitalopram (Lexapro) or duloxetine (Cymbalta).
  • Principal Investigator

    Eleanor McGlinchey, PhD
    We are conducting research to compare different ways of improving sleep and mood in teens. Treatment involves Behavioral Sleep Therapy and Interpersonal Psychotherapy for Adolescents targeting: depression trouble falling and staying asleep not feeling rested on waking feeling sleepy during the dayStudy Procedures: ~ A free, thorough diagnostic evaluation ~ A full course of therapy (8-20 sessions) at no cost ~ Saliva collection and sleep monitoring before and after treatment ~ Study evaluations and treatment will be provided at no cost to you.